Thymidine kinase cell therapy - MolMed

Drug Profile

Thymidine kinase cell therapy - MolMed

Alternative Names: Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes; HSV-Tk; TBI-0301; TK; TK cell therapy - MolMed; Zalmoxis

Latest Information Update: 03 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MolMed
  • Class Cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Leukaemia

Most Recent Events

  • 30 Jun 2017 TTY Biopharm acquires the license to commercialise and market Thymidine kinase cell therapy in Taiwan, Hong Kong, Singapore, Thailand, Philippines, Vietnam and Malaysia for haematological malignancies
  • 28 Apr 2017 Megapharm enters into an agreement with MolMed for distribution and marketing of thymidine kinase cell therapy (Zalmoxis™) in Israel for Leukaemia
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top